Physician profile
Thomas E Boyd
NPI 1518049642
$187,021.07
in general payments reported to CMS, 2019-2025
32 companies · $98.91 in 2025
The $98.91 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $24K · 2021: $13K · 2022: $51K · 2023: $30K · 2024: $300 · 2025: $98.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $3,825 · Travel and Lodging: $3,022 · Food and Beverage: $1,361 · Education: $88.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,133.50 |
| Consulting Fee | $3,825.00 |
| Travel and Lodging | $3,022.24 |
| Food and Beverage | $1,360.80 |
| Education | $88.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $86,026.42 | 2019-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $58,815.35 | 2019-2023 | Reblozyl, Onureg |
| Celgene Corporation | $23,643.13 | 2019-2024 | Reblozyl |
| Roche Molecular Systems, INC. | $14,300.00 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $3,104.18 | 2019-2020 | |
| Incyte Corporation | $151.19 | 2021-2025 | Monjuvi, Zynyz |
| Pharmacyclics LLC, An Abbvie Company | $132.48 | 2020-2022 | |
| Genentech USA, INC. | $121.50 | 2019 | |
| Beigene USA, INC. | $109.20 | 2023 | Brukinsa |
| Janssen Biotech, INC. | $95.90 | 2021-2022 | |
| Seagen INC. | $86.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.64 | 2019 | |
| Amgen INC. | $30.67 | 2020 | |
| Tempus Ai, INC | $29.96 | 2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $28.98 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $25.08 | 2022 | |
| Roche Diagnostics Corporation | $25.03 | 2019 | |
| Lilly USA, LLC | $23.75 | 2020 | |
| Kite Pharma, INC. | $22.25 | 2019 | |
| Taiho Oncology, INC. | $21.18 | 2021 | |
| Sobi, INC | $21.14 | 2022 | |
| Beone Medicines USA, INC. | $20.25 | 2025 | Brukinsa |
| Epizyme, INC. | $19.62 | 2023 | Tazverik |
| Tesaro, INC. | $18.56 | 2019 | |
| Agios Pharmaceuticals, INC. | $18.23 | 2022 | |
| Pfizer INC. | $17.25 | 2021 | |
| Glaxosmithkline, LLC. | $16.69 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.70 | 2020 | |
| Pharmaessentia USA Corporation | $13.49 | 2025 | Besremi |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.